Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Background Five-year follow-up in a trial involving patients with previously untreated stage
III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits …

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has
resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs …

Background In adults with advanced-stage Hodgkin's lymphoma, the CD30-directed
antibody–drug conjugate brentuximab vedotin combined with multiagent chemotherapy has …

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …

Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a
monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the …

An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which
results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously …

Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …

Background PD-1 blockade via pembrolizumab monotherapy has shown antitumour activity
and toxicity in patients with relapsed or refractory classical Hodgkin lymphoma. Here, we …